[go: up one dir, main page]

UY33694A - ?inhibidores de n1/n2-lactama acetil-coa carboxilasa?. - Google Patents

?inhibidores de n1/n2-lactama acetil-coa carboxilasa?.

Info

Publication number
UY33694A
UY33694A UY0001033694A UY33694A UY33694A UY 33694 A UY33694 A UY 33694A UY 0001033694 A UY0001033694 A UY 0001033694A UY 33694 A UY33694 A UY 33694A UY 33694 A UY33694 A UY 33694A
Authority
UY
Uruguay
Prior art keywords
coa carboxylase
lactama
acetil
carboxylase inhibitors
inhibitors
Prior art date
Application number
UY0001033694A
Other languages
English (en)
Inventor
Scott William Bagley
David Andrew Griffith
Robert Lee Dow
Aaron Christopher Smith
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of UY33694A publication Critical patent/UY33694A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/20—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

La invención proporciona un compuesto de Fórmula I, o una sal farmacéuticamente aceptable del mismo; en la que G es R1, R2 y R3 son como se han descrito en el presente documento; composiciones farmacéuticas del mismo; y el uso del mismo en el tratamiento de enfermedades, afecciones o trastornos modulados por la inhibición de una enzima o enzimas acetil-CoA carboxilasa(s) en un animal.
UY0001033694A 2010-10-29 2011-10-28 ?inhibidores de n1/n2-lactama acetil-coa carboxilasa?. UY33694A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40812710P 2010-10-29 2010-10-29
US201161531744P 2011-09-07 2011-09-07

Publications (1)

Publication Number Publication Date
UY33694A true UY33694A (es) 2012-05-31

Family

ID=44993633

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001033694A UY33694A (es) 2010-10-29 2011-10-28 ?inhibidores de n1/n2-lactama acetil-coa carboxilasa?.

Country Status (26)

Country Link
US (3) US8859773B2 (es)
EP (2) EP2632925B1 (es)
JP (2) JP5647356B2 (es)
KR (2) KR101529404B1 (es)
CN (2) CN104774205A (es)
AR (1) AR083578A1 (es)
AU (1) AU2011322117B2 (es)
BR (1) BR112013010310A2 (es)
CA (1) CA2815169C (es)
CY (1) CY1116405T1 (es)
DK (1) DK2632925T3 (es)
ES (1) ES2546465T3 (es)
HK (2) HK1186724A1 (es)
HU (1) HUE025078T2 (es)
IL (1) IL225779A0 (es)
MX (1) MX2013004733A (es)
NZ (1) NZ609527A (es)
PL (1) PL2632925T3 (es)
PT (1) PT2632925E (es)
RU (1) RU2540337C2 (es)
SG (1) SG189883A1 (es)
SI (1) SI2632925T1 (es)
TW (3) TW201531472A (es)
UY (1) UY33694A (es)
WO (1) WO2012056372A1 (es)
ZA (1) ZA201303882B (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2632925B1 (en) * 2010-10-29 2015-05-27 Pfizer Inc N1/N2-LACTAM ACETYL-CoA CARBOXYLASE INHIBITORS
EP2953942B1 (de) 2013-02-06 2017-10-25 Bayer CropScience Aktiengesellschaft Halogensubstituierte pyrazolderivate als schädlingsbekämpfungsmittel
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
CN103214327A (zh) * 2013-03-22 2013-07-24 郑州泰基鸿诺药物科技有限公司 一种芳香环或芳杂环三氟甲基酮化合物及其制备方法
CN104230922B (zh) 2013-06-19 2016-12-28 中国科学院上海药物研究所 一类五元杂环并吡啶类化合物及其制备方法和用途
MX2016002479A (es) 2013-09-12 2016-05-31 Pfizer Uso de inhibidores de acetil-coa carboxilasa para tratar acne vulgaris.
AU2014375265B2 (en) 2014-01-03 2018-11-01 Elanco Animal Health Gmbh Novel pyrazolyl-heteroarylamides as pesticides
CN104844509A (zh) * 2014-02-14 2015-08-19 河南工业大学 一种条件温和无金属参与的胺基喹啉衍生物的制备方法
KR101731624B1 (ko) * 2014-07-01 2017-05-04 광주과학기술원 세포 리프로그래밍 유도용 조성물
CN104610143A (zh) * 2015-02-12 2015-05-13 佛山市赛维斯医药科技有限公司 一种含硝基喹啉结构的葡萄糖激酶活化剂及其用途
ES2836399T3 (es) 2015-03-10 2021-06-25 Bayer Animal Health Gmbh Derivados de pirazolilo como agentes de control de plagas
IL243707A0 (en) 2016-01-20 2016-05-01 Galmed Res And Dev Ltd Treatment to regulate the microbiota in the intestine
US11197870B2 (en) 2016-11-10 2021-12-14 Galmed Research And Development Ltd Treatment for hepatic fibrosis
BR112019017108A2 (pt) 2017-03-16 2020-04-07 Jiangsu Hengrui Medicine Co derivados de heteroaril[4,3-c]pirimidina-5-amina, método de preparação dos mesmos, e usos médicos dos mesmos
EP3596083A4 (en) 2017-03-16 2020-12-02 Celgene CAR LLC USEFUL HETERARYL COMPOUNDS AS MK2 INHIBITORS
CA3054826A1 (en) 2017-03-16 2018-09-20 Celgene Car Llc Mk2 inhibitors, synthesis thereof, and intermediates thereto
RU2019133646A (ru) 2017-03-30 2021-04-30 Ф. Хоффманн-Ля Рош Аг Изохинолины в качестве ингибиторов hpk1
CN111406056B (zh) 2017-11-21 2023-02-28 辉瑞公司 选择性acc抑制剂的结晶2-氨基-2-(羟甲基)丙烷-1,3-二醇盐
US11612606B2 (en) 2018-10-03 2023-03-28 Genentech, Inc. 8-aminoisoquinoline compounds and uses thereof
CN109824669A (zh) * 2018-12-21 2019-05-31 西南大学 哌啶螺环酒石酸类化合物制备及应用
EP4149917A4 (en) * 2020-05-12 2024-06-19 Merck Sharp & Dohme LLC FACTOR XI ACTIVATION INHIBITORS
MX2022014553A (es) * 2020-05-21 2022-12-15 Shionogi & Co Composicion farmaceutica para tratar enfermedad de higado graso.
CN116670142A (zh) 2021-02-01 2023-08-29 细胞基因公司 Mk2抑制剂、其合成和其中间体
US20240109915A1 (en) * 2022-07-29 2024-04-04 Pfizer Inc. Novel acc inhibitors
WO2024213044A1 (en) * 2023-04-14 2024-10-17 Beijing Double-Crane Runchuang Technology Co., Ltd. Azacyclo-carbonyl-fused ring derivatives and use thereof
WO2025036472A1 (en) * 2023-08-16 2025-02-20 Pharmaengine, Inc. Spirocyclic mta-cooperative prmts inhibitor

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2002100A (en) 1932-06-27 1935-05-21 Smith Sheffield Shock absorber
JPS4925673B1 (es) * 1970-05-22 1974-07-02
DE69837903T2 (de) 1997-08-11 2008-02-14 Pfizer Products Inc., Groton Feste pharmazeutische Dispersionen mit erhöhter Bioverfügbarkeit
NZ527364A (en) 2001-02-28 2004-12-24 Merck & Co Inc Acylated piperidine derivatives as melanocortin-4 receptor agonists
WO2003018586A1 (en) 2001-08-24 2003-03-06 Pharmacia & Upjohn Company Substituted-aryl 7-aza[2.2.1]bicycloheptanes for the treatment of disease
US7001900B2 (en) 2002-02-20 2006-02-21 Pfizer Inc. Azabicyclic compounds for the treatment of disease
KR20040095239A (ko) 2002-02-27 2004-11-12 화이자 프로덕츠 인코포레이티드 Ａｃｃ 억제제
US7105526B2 (en) 2002-06-28 2006-09-12 Banyu Pharmaceuticals Co., Ltd. Benzimidazole derivatives
WO2004092179A1 (ja) 2003-04-14 2004-10-28 Nippon Soda Co. Ltd. スピロ誘導体、製造法および抗酸化薬
JP2005119987A (ja) 2003-10-15 2005-05-12 Ajinomoto Co Inc アシルスルホンアミド誘導体
AU2005247684B2 (en) 2004-05-12 2008-10-23 Pfizer Products Inc. Proline derivatives and their use as dipeptidyl peptidase IV inhibitors
WO2005113069A2 (en) 2004-05-14 2005-12-01 Research Development Foundation Use of circumin and analogues as inhibitors of acc2
UA84208C2 (en) 2004-05-25 2008-09-25 Пфайзер Продактс Инк. Tetraazabenzo(e)azulene derivatives and analogs thereof
PA8660701A1 (es) 2005-02-04 2006-09-22 Pfizer Prod Inc Agonistas de pyy y sus usos
KR20080036041A (ko) 2005-07-19 2008-04-24 머크 앤드 캄파니 인코포레이티드 아세틸 조효소 카복실라제(ａｃｃ) 억제제로서의스피로크로마논 유도체
JPWO2007013691A1 (ja) 2005-07-29 2009-02-12 武田薬品工業株式会社 スピロ環化合物
WO2007061676A2 (en) 2005-11-18 2007-05-31 Merck & Co., Inc. Spirohydantoin aryl cgrp receptor antagonists
US8735595B2 (en) 2006-02-15 2014-05-27 Abbvie Inc. Acetyl-CoA carboxylase (ACC) inhibitors and their use in diabetes, obesity and metabolic syndrome
PT2463283E (pt) 2006-04-20 2014-08-27 Pfizer Prod Inc Compostos heterocíclicos de fenil amido condensados para a prevenção e tratamento de doenças mediadas pela glucoquinase
JP2010511035A (ja) 2006-11-29 2010-04-08 ファイザー・プロダクツ・インク スピロケトンアセチルＣｏＡカルボキシラーゼ阻害剤
PE20081559A1 (es) 2007-01-12 2008-11-20 Merck & Co Inc DERIVADOS DE ESPIROCROMANONA SUSTITUIDOS COMO INHIBIDORES DE ACETIL CoA CARBOXILASA
US20100113418A1 (en) 2007-02-20 2010-05-06 Takeda Pharmaceutical Company Limited Heterocyclic compound
JP5404601B2 (ja) 2007-04-12 2014-02-05 ファイザー・インク 新規な３−アミド−ピロロ［３，４−ｃ］ピラゾール−５（１Ｈ，４Ｈ，６Ｈ）カルバルデヒド誘導体
US20090036425A1 (en) 2007-08-02 2009-02-05 Pfizer Inc Substituted bicyclolactam compounds
US7981904B2 (en) 2008-03-20 2011-07-19 Takeda Pharmaceutical Company Limited Acetyl CoA carboxylase inhibitors
EP2297163B1 (en) 2008-05-28 2015-07-08 Pfizer Inc. Pyrazolospiroketone acetyl-CoA carboxylase inhibitors
WO2009144555A1 (en) * 2008-05-28 2009-12-03 Pfizer Inc. Pyrazolospiroketone acetyl-coa carboxylase inhibitors
US8524730B2 (en) 2008-07-04 2013-09-03 Msd K.K. Spirochromanone carboxylic acids
JP2011528034A (ja) * 2008-07-14 2011-11-10 クロップソリューション，インコーポレイテッド アセチル−補酵素カルボキシラーゼの修飾因子およびその使用方法
EP2318370A1 (en) 2008-07-29 2011-05-11 Pfizer Inc. Fluorinated heteroaryls
KR101338540B1 (ko) 2008-08-28 2013-12-06 화이자 인코포레이티드 다이옥사-바이사이클로[3.2.1]옥테인-2,3,4-트라이올 유도체
TW201038580A (en) 2009-02-02 2010-11-01 Pfizer 4-amino-5-oxo-7,8-dihydropyrimido[5,4-f][1,4]oxazepin-6(5H)-yl)phenyl derivatives
CA2754685A1 (en) 2009-03-11 2010-09-16 Pfizer Inc. Substituted indazole amides
AP3179A (en) 2009-03-11 2015-03-31 Pfizer Benzofuranyl derivatives used as glucokinase inhibitors
WO2010106457A2 (en) 2009-03-20 2010-09-23 Pfizer Inc. 3-oxa-7-azabicyclo[3.3.1]nonanes
EP2427450A1 (en) 2009-05-08 2012-03-14 Pfizer Inc. Gpr 119 modulators
US20120052130A1 (en) 2009-05-08 2012-03-01 Pfizer Inc. Gpr 119 modulators
NZ596467A (en) 2009-06-05 2014-01-31 Pfizer L- ( piperidin-4-yl) -pyrazole derivatives as gpr 119 modulators
WO2011005611A1 (en) 2009-07-09 2011-01-13 Merck Sharp & Dohme Corp. Neuromedin u receptor agonists and uses thereof
EP2947082A1 (en) 2009-11-10 2015-11-25 Pfizer Inc N1-PYRAZOLOSPIROKETONE ACETYL-CoA CARBOXYLASE INHIBITORS
CA2778316A1 (en) * 2009-11-10 2011-05-19 Pfizer Inc. N-2 pyrazolospiroketone acetyl-coa carboxylase inhibitors
EP2621493B1 (en) 2010-09-30 2016-08-17 Pfizer Inc N1-PYRAZOLOSPIROKETONE ACETYL-CoA CARBOXYLASE INHIBITORS
EP2632925B1 (en) * 2010-10-29 2015-05-27 Pfizer Inc N1/N2-LACTAM ACETYL-CoA CARBOXYLASE INHIBITORS

Also Published As

Publication number Publication date
EP2632925A1 (en) 2013-09-04
ZA201303882B (en) 2014-02-26
HK1186724A1 (en) 2014-03-21
WO2012056372A1 (en) 2012-05-03
MX2013004733A (es) 2013-07-02
PT2632925E (pt) 2015-09-01
CN104774205A (zh) 2015-07-15
SI2632925T1 (sl) 2015-07-31
RU2013116924A (ru) 2014-12-10
US20120108619A1 (en) 2012-05-03
TWI507406B (zh) 2015-11-11
TW201418256A (zh) 2014-05-16
CN103189377B (zh) 2015-02-25
BR112013010310A2 (pt) 2016-11-29
NZ609527A (en) 2014-03-28
HK1209733A1 (en) 2016-04-08
AU2011322117A1 (en) 2013-05-02
KR101529404B1 (ko) 2015-06-26
CA2815169C (en) 2015-10-06
IL225779A0 (en) 2013-06-27
KR20140014078A (ko) 2014-02-05
AU2011322117B2 (en) 2015-01-22
HUE025078T2 (en) 2016-01-28
CN103189377A (zh) 2013-07-03
SG189883A1 (en) 2013-06-28
US9181252B2 (en) 2015-11-10
US20150152109A1 (en) 2015-06-04
DK2632925T3 (en) 2015-06-29
ES2546465T3 (es) 2015-09-23
CA2815169A1 (en) 2012-05-03
TW201302751A (zh) 2013-01-16
US8859773B2 (en) 2014-10-14
US20150025098A1 (en) 2015-01-22
CY1116405T1 (el) 2017-02-08
TWI441823B (zh) 2014-06-21
KR20150006899A (ko) 2015-01-19
US8993586B2 (en) 2015-03-31
PL2632925T3 (pl) 2015-10-30
EP2952514A1 (en) 2015-12-09
AR083578A1 (es) 2013-03-06
JP5647356B2 (ja) 2014-12-24
TW201531472A (zh) 2015-08-16
EP2632925B1 (en) 2015-05-27
JP2013542218A (ja) 2013-11-21
RU2540337C2 (ru) 2015-02-10
JP2015057416A (ja) 2015-03-26

Similar Documents

Publication Publication Date Title
UY33694A (es) ?inhibidores de n1/n2-lactama acetil-coa carboxilasa?.
CR20120190A (es) INHIBIDORES DE N1-PIRAZOLOESPIROCETONA ACETIL-CoA CARBOXILASA
ECSP13013038A (es) Inhibidores sustituidos de acetil-coa carboxilasa
AR081681A1 (es) METODOS Y COMPOSICIONES PARA LA ADMINISTRACION INTRATECAL DE b-GALACTOCEREBROSIDASA
CO6311079A2 (es) Derivados de aminodihidrotiazina como inhibidores de la enzima bace para el tratamiento de la enfermedad de alzheimer
EA201201648A1 (ru) Стимуляторы sgc
CR20130487A (es) 1,3-oxazinas como inhibidores de BACE1 y/o BACE2
CO7160119A2 (es) Derivados de imidazo[1,2-b]piridazina como inhibidor de cinasa
EA201390347A1 (ru) Лечение заболеваний
CR20130432A (es) 1,3-oxazinas como inhibidores de la bace1 y/o de la bace2
EA201490696A1 (ru) 3-пиримидин-4-ил-оксазолидин-2-оны в качестве ингибиторов мутантной idh
ECSP13012788A (es) Derivados de biciclo[3,2,1]octilamida y sus usos
EA201390198A1 (ru) Гетероциклическое соединение
NI201100223A (es) Derivados de imidazolidina 2 -0ne 1,3 - disustituidos como inhibidores de cyp 17
MA33939B1 (fr) 5-alcynyl-pyrimidines
PE20121617A1 (es) Derivados de oxazina como inhibidores de bace
MY167898A (en) Co-crystals and salts of ccr3-inhibitors
PE20142450A1 (es) Difluoro-hexahidro-ciclopentaoxacinilos y difluoro-hexahidro-benzooxacinilos como inhibidores de bace1
CO2017003305A2 (es) Derivados de la amida del ácido 2-[piridin-3-il]-2,3-dihidro-benzo[1,4]dioxin-5-carboxílico o del 2-[piridin-3-il]-2,3-dihidro-benzo[1,4]dioxin-5-carbonitrilo como inhibidores de aldosterona sintasa
EA201290229A1 (ru) Производные спиролактама и их применение
BR112013027395A2 (pt) inibidores de 17alfa-hidroxilase/c17,20-liase
CY1114907T1 (el) N1-πυραζολοσπειροκετονης αναστολεις ακετυλ-coa καρβοξυλασης

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20200903